802PComparative efficacy and cost-effectiveness of maximum androgen blockade (MAB), docetaxel with androgen deprivation therapy (ADT), and ADT alone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in China
ANNALS OF ONCOLOGY（2018）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要